乳腺癌组织微阵列Laminin-R与Paxllin和CD105的表达及其意义  

Expression and significance of Laminin-R,Paxllin and CD105 in human breast cancer:high throughput tissue microarray analysis

作　　者：刘风军[1] 鹿伟[1] 张建东[1] 孙德刚[1] 成玉霞[1] 孙青[1] 

机构地区：[1]山东大学附属千佛山医院肿瘤科,山东济南250014

出　　处：《中华肿瘤防治杂志》2009年第21期1657-1660,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:探讨Laminin-R、Paxllin、CD105在乳腺癌组织中的表达及其意义。方法:构建乳腺癌组织微阵列,应用免疫组织化学SP法,检测160例乳腺浸润性导管癌患者Laminin-R、Paxllin和CD105以及ER、PR的表达。结果:Laminin-R在乳腺癌组织中的表达率为55.6%(89/160),Laminin-R表达值的高低与肿瘤的组织学分级、ER表达、PR表达无关,但与淋巴结转移有关(P<0.05);Paxillin在乳腺癌中的表达率为31.88%(51/160),Paxillin表达值的高低与肿瘤的淋巴结转移、ER表达、PR表达无关,但与组织学分级有关(P<0.05);CD105微血管密度(MVD)表达值的高低与肿瘤的组织学分级、淋巴结转移、ER表达、PR表达均无关。结论:组织微阵列的建立使乳腺癌相关基因及其蛋白产物的筛选工作简便、快捷;Paxllin、Laminin与乳腺癌的生物学行为相关,且对乳腺癌的预后也有一定的提示作用。OBJECTIVE：The objective of this study was to determine the expression of Laminin-R,Paxillin and CD105 in breast carcinomas using a tissue microarray（TMA）,and investigate their clinical and prognostic valuation.METHODS：We analyzed Laminin-R,Paxillin,CD105,ER and PR expression in 160 samples of breast invasive ductal carcinomas immunohistochemically by TMA technology.Results were correlated with various clinic-pathological variables.RESULTS：The expression of Laminin-R in breast cancer was 55.6%（89/160）.The expression of LN-R was related to lymphnode metastasis（P〈0.05）,but not to pathologic grade,ER positive or PR positive.The expression rate of Paxllin in these samples is 31.88%（51/160）,and was related to pathologic grade（P〈0.05）,but not to lymphnode metastasis,ER positive or PR positive.CD105 expression（measured by microvessel density）was not related to pathologic grade,lymph node metastasis,ER positive or PR positive.CONCLUSIONS：The TMA technology makes the detection of the prognosis-associated indexes of breast cancer easily and quickly.These results suggest that both Laminin-R and Paxllin expression are associated with the biological behavior of human breast cancer,may be helpful to estimate the prognosis of breast carcinoma.

关 键 词：乳腺肿瘤/病理学 淋巴转移 免疫组织化学 

分 类 号：R737.9[医药卫生—肿瘤]